Hematocrit Within Normal Range With Testosterone "Gender-Affirming" Therapy
Mean hematocrit ranged from 41.84% to 45.68% for those receiving testosterone as gender-affirming hormone therapy
Stay updated with breaking news from Nithya Krishnamurthy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mean hematocrit ranged from 41.84% to 45.68% for those receiving testosterone as gender-affirming hormone therapy
A study found hematocrit within the normal range among patients taking testosterone for gender-affirming therapy.
Trans and gender-diverse people people who take testosterone face a risk of blood thickening, but the largest study to date in the U.S. suggests that this side effect is rare.
Mean hematocrit ranged from 41.84 to 45.68% for those receiving testosterone as gender-affirming hormone therapy.
A common concern about gender-affirming hormone therapy for transmasculine people is the risk of red blood cell volume changes and erythrocytosis, a high concentration of red blood cells, with the use of prescribed testosterone.